BridgeBio’s $299.2 Million financing round

Gunderson Dettmer advised Viking Global on the deal

BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, executed a new financing round of $299.2 million.

The round was co-led by existing investors KKR and Viking Global Investors. Other existing investors participating included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital; and they were joined by new investors Sequoia Capital, and a blue-chip long-term investor. The financing will be used to support BridgeBio Pharma’s existing drug research and development programs and expand its efforts to rapidly develop medicines for patients with unmet needs.

Genetic diseases are conditions that derive directly from mutations in their patients’ DNA. These mutations can be either inherited or spontaneous, and the diseases stemming from them include both Mendelian diseases, which tend to affect pediatric patients, and cancers. While there are more than 7,000 genetic diseases affecting 25 to 30 million Americans in aggregate, fewer than 500 drugs are approved for these conditions, leaving a significant number of patients without any therapeutic options.

BridgeBio Pharma was formed in 2015 by a team of drug research and development veterans from both the biotech industry and academia. The company seeks to translate novel scientific discoveries from universities, academic medical centers, and pharmaceutical research groups into genetically-targeted therapeutics that address the fundamental causes of disease. Its portfolio of more than 15 assets includes several in the pre-clinical stages of development, as well as four programs in or approaching pivotal trials.

Gunderson Dettmer advised Viking Global with a team including Greg S. Volkmar (Picture), Mark M. Foster and Jorge Solis

Involved fees earner: Mark Foster – Gunderson Dettmer; Jorge Solís – Gunderson Dettmer; Greg Volkmar – Gunderson Dettmer;

Law Firms: Gunderson Dettmer;

Clients: Viking Global Investors LP;

Print Friendly, PDF & Email

Author: Ambrogio Visconti